Advertisement
Advertisement
U.S. Markets open in 3 hrs 49 mins
Advertisement
Advertisement
Advertisement
Advertisement

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8552-0.0421 (-4.69%)
At close: 4:00PM EDT
0.8400 -0.02 (-1.78%)
Pre-Market: 05:34AM EDT
Advertisement
Full screen
Loading interactive chart...
  • Zacks Small Cap Research

    KTRA: FY21 Financial Results

    By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Fiscal Year 2021 Operational and Financial Results Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced fiscal year 2021 financial and operational results in a September 29 th press release and filed its 10-K with the SEC. Highlights for the fourth quarter ended June 30, 2021 and to-date include: ➢ GCAR GBM AGILE trial launch

  • PR Newswire

    Kintara Therapeutics to Present at the LD Micro Main Event Conference

    Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Saiid Zarrabian, will present a corporate overview at the 14th Annual LD Micro Main Event Conference which is being held at the Luxe Sunset Bel-Air in Los Angeles from October 12 – 14, 2021.

  • PR Newswire

    Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update

    https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2021 and provided a corporate update.

Advertisement
Advertisement